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Abstract
This article is a research summary of published and non-published 
work pertaining to Attention Deficit Hyperactivity Disorders (ADHD). 
ADHD is one of the most common child mental health disorders and 
is under-recognised in children (5.29%) and adults (2.5%). ADHD is 
highly heritable with a multifactorial pattern of inheritance. Siblings 
and parents of a child with ADHD are 4 to 5 times more likely to have 
ADHD. Methylphenidate is the first line pharmacological treatment with a 
combined response (this includes trials of other licensed amphetamines) 
rate of 95%. All clinicians working in mental health should be aware of this 
disorder, comfortable diagnosing and treating people with ADHD. Young 
people with untreated ADHD are 5 times more likely to develop antisocial 
behaviour, substance abuse and other co morbid psychiatric disorders.
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Introduction
The purpose of the review is to cover the 
epidemiology, aetiology, diagnostic criteria 
and different managements of Attention 
Deficit Hyperactivity Disorder (ADHD) with 
specific reference to practice of ADHD 
assessment and treatment management in 
Malta. This review’s target audience is for 
all clinicians to better understand what 
ADHD is and explain any misconceptions 
there are related to the medications which 
are used to manage ADHD and relate this to 
Malta. The authors will look to answer the 
questions using evidence based published 
and unpublished research.
What is ADHD?
ADHD is among the most common 
neurobehavioural disorders presenting in 
children and adolescents.1 It is characterised 
by persistent symptoms of inattention, 
hyperactivity and impulsivity according to 
Diagnostic and Statistical Manual of Mental 
Disorders 5th edition (DSM 5) present in 
two of three environments (namely home, 
school, clinic).2 The onset of the symptoms 
must have been present before the age 
of 12 years; this was increased from the 
previous DSM- IV due to the recognition 
that adults may also be diagnosed with 
ADHD, however may not clearly remember 
their symptomatology in early childhood.2 
This increase in age to diagnosis was 
thought to create a sudden rise in the 
prevalence of ADHD diagnosis around the 
world. ADHD is also classed under the term 
Hyperkinetic Disorder in the International 
Classification of Diseases 10th edition (ICD10) 
with similar characteristics including early 
onset, disorganized, ill-regulated, excessive 
activity, recklessness and impulsivity.3 The 
main difference between the DSM-5 and ICD-
10 diagnostic criteria is that in the former 
a young person (YP) may be diagnosed 
with concentration difficulties only, also 
known as Attention Deficit Disorder (ADD) 
or hyperactivity and impulsive symptoms 
but no concentration difficulties or ADHD 
combined type (attention, hyperactivity and 
impulsive symptoms). As opposed to the 
ICD-10 diagnostic criteria where a diagnosis 
is made only when all three core symptoms 
are present.3
Over the last decade there has been 
interest in the pragmatic use of social 
language in children with ADHD, this is 
the domain that manages conversational 
contexts. It was reported that as many 
as 50% of children with ADHD4 have less 
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developed pragmatic language skills 
(receptive and expressive) related to their 
typically developing peers. They also suffer 
from a developmental delay in onset of 
talking.5,6 As a result, social problems 
are reported in 52-82% of children with 
ADHD7; such as having fewer reciprocated 
friendships,8 and being more often disliked 
by their peers.9 Social problems arise due to 
symptoms of impulsivity (e.g. interrupting, 
difficulty waiting their turn), and 
inattention (e.g. not listening). This means 
that a child with ADHD has a greater chance 
of getting into trouble at school and then 
when called in to explain to the teacher 
what really happened, struggles to verbalise 
the experience, as a result may be judged 
as defiant. Subsequently peer rejection 
and education failure has been associated 
with negative long-term outcomes such as 
substance abuse, delinquency and academic 
problems.10   
Is ADHD a valid diagnosis in adults? 
ADHD is a common behavioural disorder 
that is associated with significant adult 
psychopathology, social and academic 
impairments and the risk for negative long-
term outcomes. There is no doubt that in 
many cases ADHD symptoms persist into 
adult life and cause significant clinical 
impairments. ADHD diagnosed in childhood 
tracks on through to adulthood, with 4-15% 
of adults retaining the full diagnosis and 
50-66% of YP presenting in partial remission 
of ADHD symptoms.11,12.13 The main clinical 
issue is recognition of the disorder in adults 
and quantifying the impact on adult mental 
health.12
To date there has been considerable 
debate on whether ADHD is a disorder 
solely present in YP or whether there is 
evidence that ADHD symptoms persist 
through to adult life. The latter hypothesis, 
is strongly supported by research,11 which 
found that symptoms of ADHD persist in 
65% of adults. Furthermore, it is thought 
that the ADHD symptoms do not resolve in 
adulthood, but rather adults develop the 
required social skills to control and mask 
their ADHD symptoms and adapt to social 
requirements.11 On the other hand, Moncrieff 
has argued that the validity of symptoms 
in adults do not automatically follow those 
used to diagnose children and concluded 
that the rapid growth in interest in adult 
ADHD could be the result of the drug 
companies seizing the opportunity to expand 
on a lucrative market.14 
Clinical presentation in adults
Adults with ADHD clinically present 
with more symptoms of poor attention 
(rather than hyperactivity) and ceaseless 
mental activity (distracted mind) such as 
procrastinating to start a job, then trying 
to multitask and carry out a number of 
jobs at the same, without ever finishing 
any of these jobs or finishing them with 
careless mistakes. Hyperactivity (over 
activity) is not as prominent symptom in 
adults, since adults learn to manage their 
behaviour, on the one hand through learning 
to adapt to social norms and also due to 
development (maturity) of the pre-frontal 
cortex. Mood dysregulation and lability are 
common symptoms in adults with ADHD. 
These symptoms lead to low tolerance 
of frustration, falling out with peers and 
colleagues, and as a result this effects their 
self-esteem and can lead to poor performance 
at the work place.
Adults with ADHD prefer occupations 
that are exciting and busy and that have an 
element of risk, such as: sales, stock broking, 
entrepreneurial ventures. They undergo 
frequent changes in employment, have poor 
planning abilities, e.g.: organising finances, 
handling course work at college, live and 
work in a messy environment, enjoy reckless 
driving, have trouble maintaining stability 
within their relationships and as a result 
may suffer from social isolation. They may 
choose to engage in leisure activities that 
are highly absorbing or stimulating, such as 
downhill skiing or high-contact sports. Adults 
with ADHD usually have difficulty organising 
their homes, such as cooking regular meals, 
cleaning and managing their children (e.g. 
packing their lunches, getting them to 
appointments and school on time).15 
Newly diagnosed adults with ADHD 
have presented in adulthood, the 
commonest precipitant factors for these 
include: infection (e.g. Rheumatic fever), 
degenerative disorders (e.g. early onset 
dementia), acquired brain injury (e.g. punch 
drunk syndrome) and intoxication (e.g. heavy 
metal poisoning).
There is, thus, clear evidence that ADHD 
is evident in adults but the diagnosis of adult 
ADHD is complex and the diagnostic criteria 
may be unreliable. Untreated YP with ADHD 
symptoms who are exposed to high expressed 
emotion within their families and experience 
poor social interactions, have a higher risk 
of developing conduct disorder (anti-social 
personality traits) symptoms in adulthood.16,17
Epidemiology - how common is ADHD?
The worldwide prevalence of ADHD in 
children 0 - 18 years was reported to be 
5.29% in a systematic review and meta-
regression analysis conducted by Polanczyk 
et al,18 with minor differences found between 
countries around the world. For example in 
the United Kingdom it was estimated that 
the prevalence of ADHD is 2.23% of children 
age 5-15 years.19 Whilst in the United 
States of America, the National Health 
Interview Survey (NHIS) in 2006 estimated 
the prevalence of ADHD among children age 
3-17 is 7%.20 The possible reasons for the 
significant difference in prevalence rates 
between these two countries has been widely 
debated; the most common reasons for the 
low prevalence reported in the UK is due to 
the strict adherence to ICD-102  as opposed 
to the DSM-5 in the USA. Furthermore, 
Biederman et al 19 reported that the USA 
have higher rates of social deprivation and 
experiences of trauma as a country when 
compared to the UK. In addition, one of 
the reasons apart from the more lax DSM-5 
criteria for diagnosing ADHD, is that for 
parents to get clinician reviews refunded by 
insurance, a diagnosis needs to be given. It 
is reported that ADHD is more common in YP 
living in urban rather than rural communities 
and there is a link with low socio-economic 
status. It is believed that ADHD is an under-
identified and under treated disorder.21
In adulthood, the overall pooled 
prevalence rate for adult ADHD was 
2.5%22 reported in a robustly conducted 
meta-analysis. Furthermore, Simon et 
al  reported that children do not outgrow 
the disorder (ADHD) but they outgrow 
the diagnostic criteria (ICD-10, DSM-5), 
therefore this means that there may be an 
underestimation of the true prevalence of 
this disorder in adults. Some of the reasons 
for the possible underestimation include: 
different methodological and diagnostic 
differences used in the different studies 
lead to differences in results, symptom 
recall bias, the use of DSM-5 diagnostic 
criteria to diagnose adult ADHD23 which were 
written for YP, not adults,12 and the overlap 
of the symptoms of adult ADHD with other 
disorders, as well as the adult co-morbid 
disorders.12
ADHD is more prevalent in males 
than females,24 however the ratio varies 
depending on the study design of 
populations. The reported range varies 
between 9 males is to 1 female and 2.5 is 
to 1.25 Further analysis has gone into why 
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there is such a discrepancy between males 
and females, it was hypothesised that it 
is almost socially accepted for boys to be 
hyperactive (boisterous), however girls are 
praised for being more obedient. It is also 
reported that girls tend to daydream more. 
However, day dreamers tend to still be quiet 
in class, therefore not picked up by teachers 
as having a concentration problem which 
may be effecting their overall academic 
potential.
The Evolving Concept of ADHD - is this 
a disorder created by today’s world?
The diagnosis of ADHD in children has 
been a controversial issue for many years, 
with some researchers arguing that it does 
not exist and whilst others presenting 
evidence of its existence. Similar controversy 
as expected evolved in reaction to the 
diagnosis of adults with ADHD.17 The 
skepticism about adult ADHD is influenced 
by the absence of well validated and 
universally accepted diagnostic criteria so 
adult ADHD diagnosis is significantly biased 
by current level of functioning.22
The evolution of the concept of ADHD 
goes back to the early 20th century when Still 
in 1902 described children with hyperactivity 
and poor attention as having a “defect of 
moral control”.26 The first reported use of 
a stimulant to reduce hyperactivity was by 
Bradley who used Benzedrine (stimulant) 
in children as early as 1937.27 Furthermore 
DSM-II included the earliest form of ADHD in 
their criteria, describing it as “hyperkinetic 
reaction of childhood”. This evolution of 
ADHD as a disorder continued with the latest 
edition of the DSM-5 broadening the age of 
onset from “on or before age 7” to “on and 
before age 12”.
Aetiology - Is ADHD a group of 
behaviours acquired through one 
environment or is there a genetic 
linkage?
ADHD is a developmental disorder, which 
is biologically based but environmentally 
influenced. There is no one gene which 
causes ADHD, due to interactions between 
multiple genes of small effect size.28 It 
is understood that ADHD results from an 
interacting combination of genetic and 
environmental factors.29 Genetic studies 
including twin and adoption studies indicate 
high heritability of 0.8. Family studies report 
a 57% prevalence rate in children of ADHD 
adults, whilst parents and siblings of a child 
with ADHD have an increased risk of 4 to 5 
times being more likely to have ADHD than 
the general population.30,31
ADHD is best viewed as a gene-
environment interaction. Currently there 
are two predominant theoretical models 
used to explain ADHD with a genetic 
predisposition. Each based on a distinct 
neuropsychological deficit: first executive 
dysfunction underpinned by deficient 
inhibitory control mechanisms and second, 
delay aversion, underpinned by behaving 
impulsively in order to avoid delay. Children 
with a biological predisposition will manifest 
the disorder when placed in the correct 
environment, typically one characterised by 
chaotic parenting.32
The neurobiology of ADHD suggests 
its association with cognitive processing 
deficit 24 and the pathophysiology is strongly 
linked to dopamine and norepinephrine 
neurotransmitter systems in frontostriatal 
circuitry based on brain imaging, carried out 
in neuropsychological and pharmacologic 
studies.25 Rutter et al indicated that 
the main problem lies in “behavioural 
dysregulation, executive deficits in 
inhibitory control and working memory, and 
delay aversion”.24
Neuroimaging studies of children have 
shown smaller amygdala volumes which 
were not evident in adults with ADHD.33 
Poor functioning in the striatum, frontal 
lobes, and posterior periventricular regions 
are indicated in attention problems.34 The 
hypofrontality theory suggests that ADHD is 
associated with subnormal activation of the 
prefrontal systems responsible for higher-
order motor control.35
For complex conditions such as this, 
biological based phenotypes that lie in 
the pathway from genes to behaviour 
may provide insight into the link. Such 
endophenotypes have aided the clarification 
Table 1: ADHD diagnostic criteria2,3
Symptoms Groups
Inattention
Does not attend 
Fails to finish tasks 
Cannot organise 
Avoids sustained effort 
Loses things 
Forgetful
Easily distracted
Does not listen
Hyperactivity
Fidgets 
Leaves seat in class 
Runs/climbs excessively 
Cannot play/work quiet-ly 
Always “on the go” 
Impulsivity
Talks excessively
Blurts out answers
Cannot await turn
Interrupts others
Intrudes on others 
Blurts out answers
DSM-IV ADHD ICD-10 HKD 
Either or both of following: All of following 
At least six of nine inattentive symp-toms At least six of eight inattentive symp-toms 
At least six of nine hyperactive or impulsive symptoms At least three of five hyperactive symptoms 
 At least one of four impulsive symp-toms 
Pervasiveness  
Criteria are met in one situation and impairment is present in another Criteria are met in more than one situation
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of aetiology at pathophysiology of several 
conditions in medicine. Neuropsychological 
impairments, neuroimaging and 
electrophysiological paradigms for ADHD 
show potential to move molecular genetics 
research forward. However, familial or 
genetic overlaps between these constructs 
still remain unclear. The identification of an 
‘endophenotype’ to help clarify which ‘at risk’ 
subjects will go on to develop ADHD could 
help reduce this high rate of disability.32
Environmental factors also play a role 
in the development of ADHD, these include 
severe neglect resulting in attachment 
disorders.36 A lot of work and research has 
come out of the seminal Bucharest studies, 
these are large scale studies conducted on 
children raised in very deprived conditions 
in the Romanian orphanages in the times 
of Caucescu. The findings reveal that 
children who suffered from maternal and 
nutritional deprivation at the ages of 0 to 
1 year are likely to have under developed 
right limbic systems and as a result suffer 
from emotional dysregulation.37 Further 
environmental factors include, obstetric 
complications38 although this theory is 
currently disputed, very low birth weight 
(<1000g), pre or post-natal insults, exposure 
to lead poisoning, head trauma25 and 
nutritional deficiency were expansively 
shown to contribute to the development of 
ADHD.39
Proportion of co-morbidity in people 
suffering from ADHD
If ADHD is under or misdiagnosed or not 
managed well, the prognosis for YP is poor; 
this means that there will be negative social, 
academic and vocational consequences. A 
large proportion (78%) of YP with ADHD 
tend to present with at least one co-
morbidity, the commonest include mood 
disorders (40%), substance dependence 
(35%), anxiety disorders (25%).
Furthermore, co-morbid psychiatric 
conditions are not uncommon in adults 
with ADHD. By comparing adults with ADHD 
with a sample of YP without the childhood 
psychopathology, the results show high 
rates of antisocial personality disorders 
with poorer prognosis,24 these rates vary 
from 12%12 to 23%13. Other co-morbidities 
include a high rate of substance abuse,12,24 
depression,40 anxiety and bipolar disorder41 
Social impairment, repetitiveness or 
perseveration, rigidity and inflexibility42 are 
also common co-morbidities.
Assessment process - is a one 
stop shop at a psychiatrist for 
a Methylphenidate prescription 
considered good practice?
According to NICE guidelines 200843, 
a diagnosis of ADHD should follow 
a multimodal approach. Therefore, 
the diagnosis needs to be made by a 
multidisciplinary team (MDT) specialised in 
ADHD. These include a clinical assessment of 
the YP, the ADHD symptoms in the different 
domains and settings over the past 6 
months, substantiated by using standardised 
rating scales e.g. Connors’,44 SNAP–IV45. 
The initial assessment is then followed 
by a developmental (including prenatal, 
infant and early years) and neuropsychiatric 
history (ADHD symptoms e.g. DIVA 2.046 
and assessment of co-morbidities e.g. 
anxiety, depression, learning disorders, 
autism spectrum disorders, tics, substance 
misuse), obtaining a collateral history 
and assessment of the YP’s current mental 
state. A school or home observation are 
valuable adjuncts to reviewing the YP in 
their natural environment.  Furthermore, 
obtaining a family psychiatric history, 
especially concerning learning problems, 
attention and behaviour problems, ADHD 
and tics and enquiring about all first-degree 
relatives (parents, siblings and offspring) 
is necessary. A physical examination to 
rule out medical causes of symptoms (e.g., 
serious head injury, seizures, heart problems, 
thyroid problems) or contraindications 
to medical therapy (e.g., hypertension, 
glaucoma) and to get baseline recordings 
of heart rate, blood pressure, weight and 
height are also required.
There are some controversies around 
the use of cognitive testing, however, 
there are centres of excellence such as the 
Tees Esk and Wear NHS Foundation Trust 
who recommend the use of a Weschler 
Intelligence scale for children - WISC V47 
and the administration of the TEACH.48 The 
former assesses not only the intelligence 
quotient of the child, but also gives 
an indication of the working memory 
and processing speed of the YP. Lower 
scores in these domains could give rise 
to the suspicion of attention problems. 
Furthermore, the actual assessment 
process gives the psychologist the time to 
subjectively observe the level of attention, 
hyperactivity (ability to sit) and impulsivity 
(when answering questions) the YP displays 
in clinic. On the other hand, the TEACH is a 
computer test, which objectively measures 
various forms of attention e.g. sustained and 
joint attention.
The diagnosis of ADHD is then made 
at a MDT meeting where all the reports of 
the YP are brought together and discussed. 
This diagnosis is then made based on the 
chosen diagnostic criteria and level of 
functioning of the YP. The diagnosis is 
presented together with the strengths and 
weaknesses of the YP and recommendations 
are given at a feedback session, 
accompanied by a report to parents or care 
givers and YP.
Can a diagnosis be made in children 
under the age of 5?
Published literature suggests that 
neuropsychological symptoms of ADHD 
are present from birth, but the disorder 
is rarely diagnosed at preschool age. The 
reasons for this is that the brain is still 
undergoing neural pruning and developing 
cranio-frontally under the age of 5, 
therefore most children at the age of 3 
will present with little executive function 
ability (which is derived from the pre-
frontal cortex). As a result, the brain 
would appear to be almost all overactive 
and with a poor ability to concentrate and 
make rational decisions over impulsive 
ones. As a result, an early diagnosis 
would often result in a number of false 
positive results, furthermore, side effects 
from treatment with stimulants in under 
5 year olds are as high as 33%, which is 
much higher than reported in school age 
children. However, research does report 
that ADHD symptoms could be identified 
as early as 15 months in females and 24 
months in males.49 Behavioural correlates 
to ADHD in preschool age children include 
difficult temperament and regulatory 
disturbances e.g. increased irritability, 
crying, hyperactivity and sleep problems.50 
A higher prevalence of externalising and 
internalising symptoms,51 social problems,52 
learning problems53 in preschool age 
children are all linked to an increased risk 
for developing and being given an ADHD 
diagnosis in later years.
NICE recommends that the first 
line of treatment for pre-school age 
children is parent-training and education 
programmes.43 These programmes are 
the same as those recommended for the 
parents or carers of other children with 
conduct disorder. Drug treatment is not 
recommended for preschool children with 
ADHD.
Management
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The combination of a number of 
interventions may have a role in managing 
children and adults with ADHD including 
pharmacological, neuropsychological 
and environmental interventions.34 
Methylphenidate is suggested as the first 
line of pharmacological treatments.34,41 
Other common treatments include 
Atomoxetine, and other amphetamines34,41 
such as Lisdexamfetamine a combination 
medication containing 25% levoamphetamne 
and 75% dextroampethamine. The latter 
is licensed for ADHD and narcolepsy but 
is also used as a performance enhancer 
in athletes and cognitive enhancer in 
students, apart from recreationally used as 
an aphrodisiac and euphoriant. However, 
other pharmacological treatments are 
used but with less supporting evidence, 
these include: alpha-2 agonists such as 
Guanfacine, Clonidine, antipsychotics such 
as Risperidone, Bupropion, Modafinil, and 
antidepressants with nor-adrenergic effects 
such as Amitriptyline, Imipramine, and 
Venlafaxine.41 Management of ADHD must 
be delivered by a specialist in ADHD and is 
often done in combination with parenting 
groups such as the Incredible Years53 and 
other non-pharmacological management; 
these include a range of psychological 
therapies e.g. Cognitive Behavioural 
Therapy (CBT), Behavioural Therapy, Family 
Therapy. Psychoeducation provided to the 
YP and parent is of outmost importance to 
ensure good understanding of the disorder, 
self-management of the symptoms and 
compliance to prescribed medication. 
This involves passing on the appropriate 
information and advice to parents and 
YP, informing GP, with school education 
of the care plan being provided. Special 
diets, avoidance of food colourings and 
exercise as well as other therapies such as 
neurofeedback should be discussed as part of 
the care plan.
In mild to moderate ADHD diagnosed 
in school age children, group-based parent 
training and education programmes are 
usually the first-line treatment. This may 
also include psychological treatment such 
as CBT and/or social skills training. Drug 
treatment is not indicated as the first-line 
treatment for all school-age children and YP 
with ADHD. It should be reserved for those 
with severe symptoms and impairment or for 
those with moderate levels of impairment 
who have refused non-drug interventions, 
or whose symptoms have not responded 
sufficiently to parent-training/education 
programmes or group psychological 
treatment.43,54
Pharmacological management 
Stimulants (methylphenidate and 
amphetamines) - Why should I give my 
over active child a stimulant?
The use of psychomotor stimulants to treat 
the symptoms of ADHD has been reported 
in published literature as far back as 1937 
by Bradley.27 Bradley reported significant 
improvement in school performance after 1 
week treatment of Benzedrine (stimulant) 
in 14 of 30 children with behaviour 
problems.27 Later in 1957, methylphenidate 
hydrochloride was first used as a treatment 
for ADHD.34 The efficacy for methylphenidate 
and amphetamines measured in Numbers 
Needed to Treat (NNT) is 4 and the effect 
size is 1.0, making this medication one of 
the most efficacious in all medicine.
There is little variety between the 
efficacy of slow release methylphenidate, 
with Concerta XL® having a NNT of 1.9 and 
Equasym XL® a NNT of 5.3, however, the 
lower NNT of Concerta XL® is thought to be 
a result of the poorer quality of the study 
design. The effect size of Atomoxetine is 
0.7 with a NNT of 4.2, making it also a very 
efficacious medication. If a YP is diagnosed 
correctly with ADHD then the response rate 
with one of the stimulants is 95% (refer to 
Table 255).
Methylphenidate is a central nervous 
system (CNS) stimulant. The mode of 
therapeutic action in ADHD is not exactly 
known.56 However following on from the 
hypofrontality theory24 it is understood 
that this medication stimulates the under 
developed dorsolateral prefrontal cortex 
in YP with ADHD, thereby increasing the 
concentration of the YP who is otherwise 
over attending to all diverse stimuli and 
providing negative neuronal feedback from 
the higher brain centre. This enables the YP 
in a classroom situation to follow the social 
norms and remain sitting down, rather than 
getting out of their place when this is not 
acceptable. At a neurotransmitter level, 
Methylphenidate blocks the presynaptic 
membrane dopamine transporter and thereby 
inhibits the re-uptake of dopamine and 
noradrenaline into the presynaptic neuron.41
Methylphenidate immediate release 
(Ritalin®) is a racemic mixture comprised 
of the d- and l-threo enantiomers.56 This 
medication has a half-life of 3 to 4 hours, 
which means the YP must take at least 
3 tablets to cover the school day and 
afternoon homework period. This medication 
has an on off effect, just like Paracetamol, 
and the medication is found to be out of the 
blood system within a few hours, therefore, 
there are no long-term side effects on the 
YP. However, the on off effect does mean 
that the blood level of Methylphenidate 
varies throughout the time in which it is 
effective, causing frustration to the YP 
who notices their concentration fluctuating 
throughout usage time. 
The extended release form such 
as Metadate CD® comprises both of an 
immediate release component (30% 
of the dose) and an extended release 
component (70% of the dose)55 or such as 
Concerta® which uses osmotic pressure to 
deliver methylphenidate hydrochloride at 
a controlled rate.57 The extended-release 
form of methylphenidate was initially 
developed to address the issues of multiple 
dosing and compliance issues in children 
and adolescents. It was developed in the 
early 1980s.57 Potential advantages for 
the extended-release methylphenidate 
might be the improved compliance and 
adherence to medication and avoidance of 
multi daily dosing. However, the 30/70% 
release formulation means that during 
Activation: organising, prioritising and initiating work
Focus: focusing, sustaining and shifting attention to tasks
Effort: regulating alertness, sustaining effort and processing speed
Emotion: managing frustration and regulating emotions 
Memory: utilising working memory and accessing recall
Action: monitoring and self-regulating of activities
Table 2: Behaviours that reflect executive function impairments in adults55
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the morning when the YP may need to 
concentrate the most, is the time when the 
least concentration of methylphenidate is 
released into the blood stream, and only 
reaching its peak blood concentration at 
12pm. Immediate release methylphenidate 
might have some advantages when it is used 
in older adolescents and adults for targeted 
situations such as important meetings/
events or exams.
Medikinet retard® and Equasm XL® are 
medium release preparations with half-
lives of 8 hours, the former is released in a 
50/50% release formulation, whilst the latter 
is released in a 30/70% formulation. The 
advantage of having an 8-hour preparation 
is that since insomnia and reduced appetite 
are major side effects of stimulants, not all 
children are awake for the full 12 hours and 
also, if Concerta XL® is given at 7am the YP 
would not develop an appetite till after 7pm, 
which means that the child would then have 
a late evening meal and then struggle to fall 
asleep. 
Therapeutic effects of medication include 
improvements in ADHD symptoms, peer and 
family relationships, improved learning, self-
esteem and social skills. A good response 
to methylphenidate is predicted in people 
with higher levels of inattention, restless 
behaviour and those of a younger age.
Clinical monitoring with medication 
include: pre-treatment, plotting height and 
weight on a growth chart, checking hearing 
clinically, assessing motor coordination 
and a cardiovascular examination. During 
treatment: measurement of weight and 
height, blood pressure and pulse are 
required.
What are the long-term side effects of 
taking methylphenidate?
There are no reported long-term side 
effects with methylphenidate, however, 
there are recently reported studies for 
the development of tolerance with very 
long-term use, therefore ‘drug holidays’ 
are recorded so as to reduce this risk. The 
commonest short-term side effects are sleep 
deprivation, this is avoided by not taking 
the medication after 4pm, and appetite 
suppression. xcv The latter is managed 
by encouraging the YP to take a good 
breakfast and then a large evening meal. 
Methylphenidate does not directly affect 
the growth potential of the child, however 
if the child is losing weight then there is 
a chance that the child will not achieve 
their potential height. Other common initial 
side effects include headaches, irritability, 
tics, tremor, dizziness, over stimulation 
and blurred vision, most of which disappear 
after a few weeks of taking the medication. 
Rare and dangerous side effects include 
psychosis, seizures, neuroleptic malignant 
syndrome, mania, palpitations, hypertension 
and sudden death.57 There is some research 
on the potential for drug diversions and 
misuse, however Methylphenidate does not 
have a euphoric effect on YP that have ADHD 
and need this medication for therapeutic 
purposes. 
Non-Stimulants
Atomoxetine increases noradrenaline and 
may also increase dopamine in the prefrontal 
cortex. It also blocks noradrenaline re-
uptake pumps. Atomoxetine appears to be 
an efficacious treatment of children and 
adults with ADHD, and has a half-life of 
24 hours so is prescribed as a once daily 
dose and is not a controlled drug. Its lack 
of abuse potential may be an advantage. 
The effect size is smaller (0.7) than that of 
the stimulants,58 however in recent findings 
published by,59 it was reported that once the 
controlling for parental reporting, the effect 
size of Atomoxetine was only 0.3 (which 
means a mild effect). 
There are no long-term adverse effects 
of Atomoxetine, however the notable 
immediate effects include sedation and 
fatigue, a decrease in appetite (however 
this is less than for stimulants), an increase 
in heart rate of 6 to 9 beats per minute 
and an increase in blood pressure of 2 to 
4 mmHg. Insomnia, anxiety, agitation, 
irritability, dizziness, nausea and vomiting 
are reported, however, these generally 
subside within 2 weeks of starting 
medication. Rare but potentially life-
threatening side effects include orthostatic 
hypotension, hypomania, mania, suicidal 
ideation and very rarely liver failure. 
Non-Pharmacological treatment
Non-pharmacological management 
for ADHD includes behavioural 
therapy, CBT, family therapy, social 
skills training, parenting groups, 
neurofeedback, special diets, avoiding 
eating food with artificial colouring 
from ones diet and supplementation 
with free fatty acids such as omega 3 
and 6. This treatment could be used 
alone or in combination with stimulant 
medication and must be maintained 
over an extended period of time for 
more positive and long lasting results. 
The results on non-pharmacological 
studies remain mixed. In the large 
MTA follow up study60 there was no 
difference found between those YP 
prescribed stimulant medication 
alone compared to those receiving 
a combination of medication and 
psychological treatment.60 There are 
some small scale individual studies 
which demonstrate the benefit of 
omega 3 and 6 fatty acids,61 cognitive 
training,62 parenting groups54 and 
removal of diets containing artificial 
colouring, however in a large and 
robust systematic review and meta-
analysis, it was found that only in the 
case of food colouring was there some 
evidence to show the benefit on the 
treatment of ADHD symptoms and all 
the rest showed no difference when 
compared to placebo effect.63 
Conclusion
ADHD is a common neurodevelopmental 
disorder which is possibly under-recognised 
in mental health settings and in community 
Table 3: Medication efficacy in psychiatry65
Medication Efficacy Numbers Needed 
to Treat (NNT)
Effect Size 
(range 0-1)
Methylphenidate 4 1.0
Amfetamine 4 1.0
Atomoxetine 4 0.7
SSRI for depression in adults 10 0.5
Antipsychotics for Schizophrenia in adults 10 0.25
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Key points
•	 ADHD is a common neurodevelopmental disorder which is possibly under-recognised in 
children and adults
•	 ADHD is easy to treat with 95% of correctly diagnosed patients responding  to 
treatment
•	 To ensure the accuracy, a diagnosis of ADHD should be made following a multimodal 
assessment which is carried out by a multidisciplinary team trained in ADHD
•	 In younger children there is evidence to support that parenting groups and 
psychological treatment is effective, although the evidence is mixed regarding if 
combination with medication could have an added effect
•	 All general psychiatrists should be aware of and comfortable with making the diagnosis 
of ADHD and treating both children and adults
both in children (5.29%)18 and adults 
(2.5%).18 ADHD is a highly heritable disorder 
0.76 and parents and siblings of a child with 
ADHD are 4 to 5 times more likely to have 
ADHD.30,31 ADHD is easy to treat with 95% 
of correctly diagnosed patients (children 
or adults) responding  to treatment11,64 
Methylphenidate is suggested as the first 
line of pharmacological treatments.34,41 For 
most patients with ADHD symptoms, these 
should be safely managed by the use of a 
single medication, however there is evidence 
where methylphenidate immediate release 
has been added to augment the effect of 
methylphenidate extended release and also 
that of Atomoxetine, when the clinical 
response remains inadequate. There is 
initial good evidence which suggests that 
stimulants and alpha-2 agonist combinations 
may have an additive effect, improving 
effectively and reducing adverse side effects. 
The evidence for non-pharmacological 
treatment of ADHD remains mixed,63 there 
is some evidence to support the removal of 
food supplements from the diet of YP with 
ADHD and combination of psychological 
treatments and parenting groups with 
medication could have an added effect.60 All 
general psychiatrists should be aware of this 
disorder and be comfortable with making 
the diagnosis and treating both children and 
adults with ADHD.
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